Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

PFIZER SINGLE-SOURCE Rx DRUGS WILL BE FREE FOR UP TO 1 MIL. low-income patients through community, migrant and homeless health centers under Pfizer's "Sharing the Care" program. Intended for patients living at or below the poverty line in all 50 states, the Pfizer program was scheduled to be announced Aug. 14 at the National Governors' Association annual meeting in Tulsa, Okla. First-year costs, including program startup expenditures, are estimated by Pfizer at $10 mil.-$12 mil. The program is sponsored jointly by Pfizer, NGA and the National Association of Community Health Centers (NACHC). In a press statement, Pfizer Vice Chairman Edward Bessey, president of the firm's U.S. Pharmaceuticals Group, said the program's use of approximately 340 health centers enables Pfizer to "get our medicines to impoverished patients in urban and rural areas now, while the plan for reforming the U.S. health care system takes shape." It is estimated that 500,000 to 1 mil. patients at or below the poverty line but ineligible for Medicaid will benefit from the program in its first year. The program expands earlier Pfizer-NGA efforts to provide health care to the needy and is based on programs established in several states since 1990. Pfizer has provided its product line free since 1990 to Kentucky's Health Care Access Foundation, a nonprofit cooperative of health care professionals serving patients who live below the poverty line and lack insurance but are ineligible for entitlement programs. Pfizer said it helped establish a similar program in Arkansas in 1992. In late 1992 and early this year, Pfizer said, the company and Johnson & Johnson began providing pharmaceuticals free to two established health care clinics in West Virginia and to South Carolina's Commun-I-Care program. Through these programs, "Pfizer and other pharmaceutical firms provide access to pharmaceutical products at no charge for qualified low-income Americans," the press release states. Pfizer is donating drugs from its entire line, many of which treat illnesses common in low-income patients, the statement continues. The products include Procardia XL, Diflucan, Zithromax, Glucotrol, Norvasc, Cardura, Cefobid, Zoloft, Unasyn, Streptomycin and Geocillin. The Pharmaceutical Manufacturers Association's 1992 Directory of Prescription Drug Indigent Programs lists Pfizer as a participant in the Kentucky and Arkansas programs and contains entries for the Diflucan patient assistance program and the general Pfizer indigent patient program, which covers all products but Diflucan. On Aug. 5, the Senate Special Committee on Aging released a four-page update on how patients can obtain medications free. In July, PMA voted to continue its efforts disseminating information about indigent patient programs offered by 42 member companies. In a year of operation the programs have received more than 250,000 patient requests for assistance in obtaining medication ("The Pink Sheet" July 12, T&G-5). Planned participants in the Sharing for Care announcement, in addition to Bessey, included South Carolina Gov. Carroll Campbell, Jr. (R), the incoming NGA chairman; New Jersey Gov. James Florio (D); Colorado Gov. Roy Romer (D); and NACHC President Jessie Trice.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts